OSR (NASDAQ:OSRH – Get Free Report) is one of 89 public companies in the “UNCLASSIFIED” industry, but how does it contrast to its rivals? We will compare OSR to similar businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.
Analyst Recommendations
This is a breakdown of current ratings and target prices for OSR and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| OSR Competitors | 254 | 268 | 217 | 3 | 1.96 |
As a group, “UNCLASSIFIED” companies have a potential upside of 141.36%. Given OSR’s rivals stronger consensus rating and higher possible upside, analysts plainly believe OSR has less favorable growth aspects than its rivals.
Volatility and Risk
Earnings & Valuation
This table compares OSR and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OSR | N/A | -$2.41 million | -0.54 |
| OSR Competitors | $42.00 million | -$18.84 million | 69.05 |
OSR’s rivals have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares OSR and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | N/A | -6.66% | -4.90% |
| OSR Competitors | 0.86% | 0.95% | 0.80% |
Institutional & Insider Ownership
55.3% of OSR shares are owned by institutional investors. Comparatively, 52.0% of shares of all “UNCLASSIFIED” companies are owned by institutional investors. 60.6% of OSR shares are owned by insiders. Comparatively, 42.9% of shares of all “UNCLASSIFIED” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
OSR rivals beat OSR on 9 of the 13 factors compared.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
